Search

Displaying results 3251 - 3260 of 6198 in total
  1. Drug

    Ornithine

    go.drugbank.com/drugs/DB00129
    ApprovedInvestigationalNutraceutical

    Produced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine.

  2. Drug

    BW-A 58C

    go.drugbank.com/drugs/DB06740
    Experimental

    metabolite in man in vivo and also in human liver microsomes, where this is catalysed primarily by a 54 kDa CYP2C9 form of cytochrome P450, P450hB20-27. … BW-A 58C, also known as 2-(4-tert-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone, is an experimental naphthoquinone antimalarial drug which undergoes extensive alkyl hydroxylation to a single t-butylhydroxy

  3. Drug

    Cholecystokinin

    go.drugbank.com/drugs/DB08862
    ApprovedInvestigationalWithdrawn

    Normally, it is an endogenous hormone but is available commercially for diagnostic processes and replacement in pancreatic insufficiency [L1646, L1647, L1648]. in the octapeptide form. … CCK also acts as an appetite suppressant and has been studied for weight management regimens [L1637].

  4. Drug

    Human Interleukin 8

    go.drugbank.com/drugs/DB16456
    Investigational

    Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).

  5. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    MPI-674 is an aromatase inhibitor (AI) with a well-established, multi-year chronic safety and tolerability profile. … AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen.

  6. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection.

  7. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [L51194] The mainstay of cGVHD treatment are systemic corticosteroids, but they are ineffective in 30-50% of cases. … [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD.

  8. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and to decrease the synthesis of TNF alpha.

  9. Drug

    CT120

    go.drugbank.com/drugs/DB18181
    Investigational

    CT120 is an investigational autologous CD19/22 targeted CAR-T cell immunotherapy.

  10. Drug

    Butorphanol

    go.drugbank.com/drugs/DB00611
    ApprovedIllicitVet approved

    A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.